Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Epidemiology of visceral leishmaniasis in Algeria: an update

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Adel, A. en_US
dc.contributor.author Boughoufalah, A. en_US
dc.contributor.author Saegerman, C. en_US
dc.contributor.author De Deken, R. en_US
dc.contributor.author Bouchene, Z. en_US
dc.contributor.author Soukehal, A. en_US
dc.contributor.author Berkvens, D. en_US
dc.contributor.author Boelaert, M. en_US
dc.date.accessioned 2014-09-25T13:39:40Z
dc.date.available 2014-09-25T13:39:40Z
dc.date.issued 2014 en_US
dc.identifier.issn 1932-6203 en_US
dc.identifier.doi http://dx.doi.org/10.1371/journal.pone.0099207 en_US
dc.identifier.other ITG-B1B; ITG-B4A; ITG-B7A; ITG-HLA; MULTI; DBM; U-VEPID; DPH; U-ECTD; JIF; DOI; FTA; E-only; OAJ; Abstract; UPD56 en_US
dc.identifier.uri http://hdl.handle.net/10390/7795
dc.description.abstract Visceral leishmaniasis (VL), a zoonotic disease caused by Leishmania infantum, is endemic in Algeria. This report describes a retrospective epidemiological study conducted on human VL to document the epidemiological profile at national level. All human VL cases notified by the National Institute of Public Health between 1998 and 2008 were investigated. In parallel all VL cases admitted to the university hospitals of Algiers were surveyed to estimate the underreporting ratio. Fifteen hundred and sixty-two human VL cases were reported in Algeria between 1998-2008 with an average annual reported incidence rate of 0.45 cases per 100,000 inhabitants, of which 81.42% were in the age range of 0-4 years. Cases were detected year-round, with a peak notification in May and June. One hundred and seventy patients were admitted to the university hospitals in Algiers in the same period, of which less than one in ten had been officially notified. Splenomegaly, fever, pallor and pancytopenia were the main clinical and laboratory features. Meglumine antimoniate was the first-line therapy for paediatric VL whereas the conventional amphotericin B was used for adult patients. Visceral leishmaniasis in Algeria shows the epidemiological profile of a paediatric disease with a decrease of the annual reported incidence rate. However, vigilance is required because of huge underreporting and an apparent propagation towards the south. en_US
dc.language English en_US
dc.subject Protozoal diseases en_US
dc.subject Kala azar en_US
dc.subject Visceral en_US
dc.subject Leishmaniasis en_US
dc.subject Leishmania infantum en_US
dc.subject Vectors en_US
dc.subject Sandflies en_US
dc.subject Phlebotomus argentipes en_US
dc.subject Epidemiology en_US
dc.subject Incidence en_US
dc.subject Case reports en_US
dc.subject Detection en_US
dc.subject Seasonality en_US
dc.subject Clinical manifestations en_US
dc.subject Splenomegaly en_US
dc.subject Fever en_US
dc.subject Pallor en_US
dc.subject Pancytopenia en_US
dc.subject Meglumine antimoniate en_US
dc.subject Amphotericin B en_US
dc.subject Algeria en_US
dc.subject Africa, North en_US
dc.title Epidemiology of visceral leishmaniasis in Algeria: an update en_US
dc.type Article-E en_US
dc.citation.issue 6 en_US
dc.citation.jtitle PLoS ONE en_US
dc.citation.volume 9 en_US
dc.citation.pages e99207 en_US
dc.identifier.pmid http://www.ncbi.nlm.nih.gov/pubmed/24949958 en_US
dc.citation.jabbreviation PLoS ONE en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record